NeonMind Biosciences

Rob is a seasoned pharmaceutical executive with over 25 years of experience across numerous therapeutics areas including obesity, addiction and neurologic disorders. He was the former President, CEO and Director of Mind Medicine Inc. (NEO:MMED), a pioneer in psychedelic drug development, prior to Mind Medicine becoming the first psychedelics company to list on a stock exchange.

For over two years, Rob was President & CEO of Cipher Pharmaceuticals Inc. (TSX:CPH), where he led the company to positive EBITDA through the execution of seven business development transactions to rapidly expand the product pipeline. At Watson Pharmaceuticals, Rob led the integration of major M&A transactions including Warner Chilcott (~$5B global acquisition), Forest Laboratories (~$28B global acquisition) and Allergan (~$66B global acquisition).”